Amelia Armour is a venture investor based in Cambridge and a partner at Amadeus Capital Partners, where she focuses on early-stage deep-tech and healthcare investments. Her work centers on science-led companies, often including university spin-outs and technically complex businesses that require patient capital and long development timelines.

Her portfolio includes high-profile deep-tech companies such as Riverlane and Paragraf, and her scientific background helps her work effectively at the interface of research and commercialization. While she is not a neurotech-only investor, she is highly relevant for neurotech-adjacent companies developing advanced sensors, diagnostics, AI-enabled healthcare tools, or novel hardware.

Her geographic focus is the United Kingdom, especially the Cambridge-Oxford-London innovation corridor. She is particularly important for founders emerging from academic environments who need both early capital and experienced board-level support.